MarketCap
Facebook
X
TelegramQuarterly report 2021-Q3
added 05-23-2026
Arena Pharmaceuticals DSO Ratio 2011-2026 | ARNA
Annual DSO Ratio Arena Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 8.16 K | 410 | 157 | 34.8 | 14.5 | 118 | 70.7 | 36.2 | 40.8 | 58.9 | 38.4 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.16 K | 14.5 | 831 |
Quarterly DSO Ratio Arena Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | 46.7 | 335 | 50.9 | 119 | 219 | 0.47 | 33.8 | 46.8 | 64.4 | 147 | 14.1 | 27.4 | 28.7 | 15.6 | 12.4 | 51.3 | 45.6 | 51.4 | 49.7 | 38.5 | 81.5 | 59.3 | 32.9 | 57.4 | 31.7 | 81.4 | 161 | 172 | 1.71 | 135 | 147 | 653 | 44.8 | 33.6 | 57.6 | 53.2 | 36.8 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 653 | 0.47 | 87.5 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
FSD Pharma
HUGE
|
2.94 K | - | 5743.5 % | $ 69.7 M |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
58.2 | $ 1.7 | 3.03 % | $ 452 M |  Britain |
 |
Happiness Biotech Group Limited
HAPP
|
29 | - | 1.35 % | $ 17.8 M |  China |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
Coherus BioSciences
CHRS
|
559 | $ 1.61 | 2.55 % | $ 189 M | USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
CRISPR Therapeutics AG
CRSP
|
1.1 K | $ 50.36 | 0.92 % | $ 4.53 B |  Schweiz |
 |
Compugen Ltd.
CGEN
|
400 | $ 2.8 | 7.28 % | $ 262 M |  Israel |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M | Britain |
 |
Affimed N.V.
AFMD
|
31.4 | - | -34.95 % | $ 21.5 M |  Germany |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | - | $ 651 M | USA |
 |
Eton Pharmaceuticals
ETON
|
39.1 | $ 32.59 | -6.89 % | $ 877 M | USA |
 |
Celyad Oncology SA
CYAD
|
64.4 | - | - | $ 12.5 M |  Belgium |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
Generation Bio Co.
GBIO
|
47.6 | - | - | $ 344 M | USA |
 |
IMV
IMV
|
2.16 K | - | - | $ 13.1 M | Canada |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Cyclacel Pharmaceuticals
CYCCP
|
3.66 K | - | -4.36 % | $ 27 M | USA |
 |
Anika Therapeutics
ANIK
|
76.5 | $ 14.88 | -0.93 % | $ 213 M | USA |
 |
Advaxis
ADXS
|
3.28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M | Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
126 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.4 | -1.16 % | $ 5.6 M | Israel |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |